Gibco CTS TrueCut Cas9 Protein is our highest performing CRISPR-Cas9 protein, engineered to deliver maximum ribonucleoprotein (RNP)-editing efficiency. This protein is manufactured in compliance with standards for Ancillary Materials for Cell, Gene and Tissue-Based Products and is subjected to stringent quality specifications. It is provided in a high-concentration and large-scale format for process development and clinical research applications.
Features of CTS TrueCut Cas9 Protein include:
• Consistent high editing efficiency
—superior CRISPR-Cas9 editing efficiency in all tested cell lines including primary immune cells (>90% editing in primary T cells)
• Higher stringency manufacturing
—manufactured to meet the standards for Ancillary Materials for Cell, Gene, and Tissue-Based Products including USP <1043>, Ph.Eur. 5.2.12, and ISO 20399, following the principles of 21 CFR Part 820 in a FDA-registered manufacturing site
• Aseptic manufacturing
—entire process completed using single-use technology
• Extensive safety testing
—includes sterility, endotoxin, mycoplasma, residual nucleic acids, and proteins
• Sterile filling
—finished product is vialed in a Class A/B (Class 100 and ISO 5 equivalents) cleanroom
• Traceability documentation
—COA, COO, Drug Master Files, and Regulatory Support Files are available
CTS TrueCut Cas9 Protein is a Streptococcus pyogenes Cas9 (wt) protein, produced by recombinant DNA technology in E. coli for genome editing with CRISPR technology. Cas9 protein forms a very stable RNP complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. Incorporation of NLS aids delivery to the nucleus, increasing the editing efficiency and on-target cleavage.
If you would like to evaluate our TrueCut Cas9 protein or conduct small-scale research experiments, we recommend using our TrueCut Cas9 Protein v2
For Research Use or Non-Commercial Manufacturing of Cell-Based Products for Clinical Research. Caution: Not intended for direct administration into humans or animals.